The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide (s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.
本公开涉及膜转运蛋白NaPi2b(SLC34A2)作为治疗靶点,包括免疫疗法,特别是癌症治疗。已经确定了包含SLC34A2
氨基酸312-340的SLC34A2表位肽作为使用单克隆
抗体MX35鉴定的卵巢癌表位。本发明还涉及使用SLC34A2,特别是SLC34A2肽生成具有抗肿瘤或抗癌活性或刺激免疫反应的
抗体。本发明还涉及针对NaPi2b(SLC34A2)和SLC34A2肽(s)的
抗体,包括经过修饰的、嵌合的、单链的和人源化的
抗体。还提供了用于产生免疫反应和治疗肿瘤和癌症的方法。提供了用于筛选和鉴定针对SLC34A2,包括SLC34A2表位肽和其他
抗体的化合物的检测方法。